InsiderTrades.com logo
New Stock Alert. It's On Fire
From Stock Street News   |   Ad
Read about the small cap that might make history with its nanotechnology.
Read more

ANP Insider Trading (Antisense Therapeutics)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): A$0.00
Insider Selling (Last 12 Months): A$0.00

Antisense Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Antisense Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Antisense Therapeutics Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for ANP up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Next Plant-Based Unicorn
From MicroSmallCap   |   Ad
The plant-based industry has been ignited. Pay close attention to this stock.
Learn more.

Antisense Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/3/2020Robert MosesInsiderIssued90,201A$0.10A$9,020.10
12/23/2019Graham MitchellInsiderIssued7,000,000A$0.09A$609,000.00
12/20/2019Robert MosesInsiderBuy100,000A$0.09A$8,800.00
12/18/2019Graham MitchellInsiderExercise48,036A$0.08A$3,842.88
12/16/2019Robert MosesInsiderBuy618,888A$0.08A$49,511.04
12/3/2019Robert MosesInsiderBuy800,000A$0.08A$64,000.00
11/2/2018Mark DiamondInsiderBuy157,856A$0.04A$5,840.67
See Full Table
Insider Buying at Antisense Therapeutics?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Antisense Therapeutics and related companies.

SEC Filings (Institutional Ownership Changes) for Antisense Therapeutics (ASX:ANP)

Antisense Therapeutics Limited, a biopharmaceutical company, engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d that has completed Phase IIa for the treatment of multiple sclerosis, Duchennes Muscular Dystrophy, multiple sclerosis, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited is based in Toorak, Australia.
Read More on Antisense Therapeutics

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

1,318,309 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Antisense Therapeutics?

Antisense Therapeutics' top insider shareholders include:
  1. Graham Mitchell (Insider)
  2. Robert Moses (Insider)
Read This Before You Invest In Gold
From The Gold Letter   |   Ad
While inflation is about to hit all time highs. Many investors are thinking of putting their money into gold. But is that the best play? Maybe not, because gold prices are also at an all time high. ($2,000/oz)
Click Here To See the "Backdoor Gold Play"